A major new NHS trial could bring Britain a step closer to diagnosing some of the deadliest cancers through a simple blood test, potentially giving thousands of patients a better chance of survival.
More than 20,000 people across England are expected to take part in the ambitious research programme, which will investigate whether advanced blood tests can identify signs of 13 different cancers, including some that are notoriously difficult to detect in their early stages.
The £8.5 million Government-funded study, known as STRIDE-RCT, will involve more than 200 GP practices and is being led by scientists at the University of Birmingham.
It represents a significant investment in British medical research, combining developments in cancer biology, blood analysis and artificial intelligence to tackle one of the greatest challenges facing modern healthcare: detecting cancer before it becomes life-threatening.
Among the diseases researchers hope to identify earlier are pancreatic, ovarian, bowel, liver, stomach, kidney, bladder and prostate cancers.
The study will also investigate cancers affecting the oesophagus, small bowel, bile ducts, gallbladder and womb lining.
Unlike traditional investigations, which may require patients to undergo several different procedures, the experimental technology aims to identify warning signs of multiple cancers from a small blood sample.
Some of the tests look for traces of genetic material released by cancerous tumours into the bloodstream. Others examine proteins associated with cancer, while artificial intelligence can help interpret complex biological patterns.
The ultimate ambition is to provide doctors with more reliable information about whether cancer may be responsible for a patient’s symptoms and which part of the body requires further investigation.
Why earlier diagnosis could save lives
The importance of catching cancer early cannot be overstated.
Across England, approximately 71,000 people are diagnosed with pancreatic, stomach, liver, ovarian or bowel cancer every year. Almost 35,000 people die from these diseases annually.
For many patients, the greatest difficulty is that early symptoms can resemble relatively harmless conditions.
Persistent bloating, indigestion, stomach discomfort and changes in bowel habits can have numerous explanations, making it challenging for GPs to distinguish between common complaints and potentially serious illnesses.
By the time some cancers are identified, they may already have spread to other parts of the body.
The difference in survival prospects can be dramatic.
Around 90 per cent of patients diagnosed with bowel cancer at its earliest stage survive for at least five years. For those diagnosed at stage four, that figure falls to approximately 10 per cent.
Researchers hope the new blood tests could help doctors recognise concerning cases sooner, allowing patients to receive specialist investigations and treatment while their disease remains more manageable.
Thousands of NHS patients to be invited
The new trial will recruit patients aged 45 and over who visit their GP with symptoms that could potentially indicate abdominal cancer.
Most volunteers will be asked to provide just one or two tubes of blood alongside their normal medical investigations.
Three different testing technologies will be assessed, with researchers examining how accurately they detect potential cancer signals and whether they improve decisions about referrals.
Importantly, the tests will not replace established diagnostic procedures.
A blood test suggesting cancer is present would still need to be followed by further examinations, scans or other investigations before a diagnosis could be confirmed.
Equally, a reassuring blood test would not necessarily mean a patient was free from cancer.
The research will therefore examine both the benefits and limitations of the technology, including whether it can help the NHS direct specialist resources towards patients most likely to need them.
British scientists leading the research
The University of Birmingham is at the forefront of the programme, which is funded through the National Institute for Health and Care Research.
The project is scheduled to run from November 2026 until October 2031, reflecting the extensive scientific evaluation required before new diagnostic methods can be introduced more widely.
The study comes at an important moment for cancer blood-test research.
An earlier major NHS investigation, involving more than 142,000 volunteers, examined the Galleri multi-cancer detection test.
Although that trial demonstrated the ability to identify cancer signals and produced some encouraging findings concerning the most advanced cancers, it did not achieve its primary objective of reducing the combined incidence of stage three and stage four diagnoses.
The results, published in leading medical journals in September, underline why rigorous clinical trials remain essential, even when new medical technologies appear promising.
The latest programme takes a different approach by concentrating on people who have already developed symptoms, rather than testing a broad population without symptoms.
Researchers will assess whether using blood tests alongside a GP’s clinical judgement can lead to more effective investigations and earlier diagnoses.
If the findings are positive, the technology could eventually become an important addition to the NHS’s existing cancer diagnostic services.
For patients facing the uncertainty of unexplained symptoms, that could mean fewer delays, more targeted investigations and a better opportunity to begin treatment before the disease advances.
For Britain, the trial is also another opportunity to demonstrate the strength of its medical research institutions and their ability to develop innovations with the potential to benefit patients far beyond the UK.
But the central question remains whether these technologies can deliver measurable improvements in diagnosis and, ultimately, patient outcomes.
That is what the next five years of research will seek to establish.
